behind the rapid growth of bloomage bio's medical beauty business
2024-09-21
한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
recently, huaxi bio released its 2024 semi-annual report, which showed that during the reporting period, the company's medical terminal business revenue reached 743 million yuan, achieving a high growth rate of 51.92%. among them, huaxi bio's skin medical products achieved revenue of 555 million yuan in the first half of 2024, a year-on-year increase of 70.14%.
since proactively "putting the brakes" on its medical beauty business in 2021, bloomage's medical beauty business has been undergoing a profound transformation in recent years. however, since last year, bloomage's medical beauty business has shown a straight-line upward trend, with significant results.
deeply cultivate the medical beauty market and never forget the original intention of "innovation"
in recent years, the penetration rate of the medical beauty industry has continued to rise, showing a booming development trend. a securities research report pointed out that the continuous increase in the penetration rate of beauty care projects is due to the fact that in the medical beauty industry chain, from upstream raw material suppliers to downstream product manufacturers, they are actively conducting innovative research and development, and continuously promoting the launch of new products in the medical beauty industry. huaxi bio's medical beauty business fits this industry development trend. based on the company's six major categories of bioactive substances, huaxi bio's drug and device research and development promotes the emergence of safer and more effective drug and device terminal products by strengthening material application research and process innovation, and continuously consolidates its position in the industry.
according to the 2024 semi-annual report released by huaxi bio, the company currently has 96 pharmaceutical and medical device projects under development. it has also obtained 5 class ii medical device registration certificates in china, covering a variety of medical device products such as recombinant collagen wound dressings, recombinant collagen wound dressings, and scar repair silicone gel, and has obtained 7 medical device registration certificates internationally.
it is particularly noteworthy that in july 2024, huaxizi bio's class iii medical device "sodium hyaluronate complex solution for injection" (trade name: runzhi gege) was approved for marketing by the national medical products administration (nmpa). this is also china's second class iii certificate for complex solution medical devices.
as an important innovative achievement of bloomage biotechnology in the medical beauty market, "runzhi gege" adopts exclusive triple molecule self-crosslinking technology to achieve 0 crosslinking agent addition but dense product structure with viscoelasticity, and cooperates with patented compound amino acid clusters to promote collagen, thus bringing consumers a more focused and effective neck rejuvenation solution. in addition, since the field of compound solutions has long faced problems such as monopoly and irregular use, the approval of bloomage biotechnology's license not only broke the long-standing industry monopoly, but also promoted the process of industry compliance development.
according to huaxi bio's 2024 semi-annual report, the company's medical beauty business sales revenue has steadily increased, the expense rate has steadily decreased, and the operating quality has gradually improved. compared with the same period last year, the revenue of skin medical products increased from 326 million yuan to 555 million yuan, and the growth rate jumped from 56.76% to 70.14%. in addition, its differentiated advantage category, micro-cross-linked runzhi baby needle, has achieved remarkable year-on-year revenue growth of more than 200%.
adhere to the differentiation strategy and provide "one-stop" solutions
the reason why the medical beauty business can quickly achieve a strong breakthrough is closely related to the in-depth layout of this business field under the curtain of huaxizi bio's transformation.
according to the financial report, huaxi bio's medical beauty business has insisted on reform in recent years and continued to improve its product system. by focusing on facial rejuvenation and striving to create a layered anti-aging aesthetic, it is committed to providing a one-stop overall solution for those seeking beauty.
at the product level, bloomage biotechnology insists on product familyization, continues to focus on and dig deep into the differentiated advantages of its own products, and builds a complete product system. for example, the core medical beauty brand runzhi, with the concept of layered anti-aging, has successively launched a number of matrix products targeting the needs of different skin levels - runzhi natrual, no. 2, no. 3 and no. 5, as well as the micro-cross-linking track for skin rejuvenation and long-term solutions - runzhi baby needle, while runzhi zhenhuo is marketed as a post-operative skin care product. in addition, bloomage biotechnology's medical beauty products also meet the diversified needs of the entire post-operative care cycle through the "medical + makeup" multi-product series matrix to improve customer and consumer satisfaction.
in terms of marketing and market, huaxi bio adheres to the medical heights and collaborates with external experts to establish a unified approach for layered anti-aging and contour aesthetics theoretical systems. at the same time, it combines with professional platforms to focus on medical delivery, and has linked with more than 2,000 external doctors during the reporting period.
in terms of operations, bloomage's medical beauty sector is also continuing to expand its coverage of medical beauty institutions. data shows that during the reporting period, bloomage's medical beauty institution coverage rate and the number of single-institution cooperative products have significantly increased, with the medical beauty institution coverage rate increasing by more than 50% year-on-year.
as a biotechnology company driven by synthetic biology technology innovation and a biomaterials full industry chain platform company, bloomage's advantages of "synthetic biology leadership + full industry chain integration" have laid a solid foundation for the development of all business lines such as medical beauty. with the completion of the pharmaceutical-grade pilot results transformation center in june 2024, bloomage's world's largest and most extensive pilot results transformation platform will be fully completed, which will undoubtedly accelerate the efficiency of transforming scientific research results into market applications and inject strong momentum into the company's core business.
in the future, huaxi bio will seize market opportunities, rely on its leading synthetic biology materials and technology platform advantages, adhere to the strategic layout thinking of "continuous breakthroughs in materials technology + comprehensive diversification of product efficacy", and continuously iterate and innovate its product matrix. while meeting consumers' refined indications and treatment needs, it will continuously enhance the market competitiveness of its medical beauty business and expand the industry's development space.
